Rationale: Medication nonadherence is the highest determinant of relapse in schizophrenia. Interventions that help patients remain on medication for extended periods could substantially improve clinical outcomes. Significance: The revised R01 renewal application will advance the development of an implantable long-term risperidone delivery system to improve medication adherence in schizophrenia. Achieving this goal could improve the health and quality of life for millions of people with schizophrenia and their families. Progress: We completed both Aims during the previous period by performing in vitro-in vivo correlation (IVIVC) modeling for sterile, biodegradable implants. In the previous 2-year funding period, we developed a long-term risperidone delivery system using the biodegradable polymer poly-lactide-co-glycolide (PLGA). First, we determined in vitro risperidone release from multiple types of implants by varying lactide to glycolide ratios. We then determined in vivo serum risperidone concentration from a New Hypothesis: We propose that the benefits of long term delivery systems extend beyond a safety net against relapse. Preliminary data suggest that steady state infusion of antipsychotic medication from implants could provide consistent modulation of dopaminergic tone intermittent oral administration allowing the brain to remodel in a stable therapeutic environment. Studies in this application would test this hypothesis using animal models of antipsychotic efficacy and side effects. Proposed Studies: The current application would determine how constant risperidone infusion from implants affects behavioral (Aim 1), biochemical (Aim 2) and molecular (Aim 3) measures of efficacy and side effects comparison to three times daily oral administration in rodents.

Public Health Relevance

Medication nonadherence is the highest cause of relapse in schizophrenia. Interventions that help patients remain on medicine would substantially improve quality of life for millions of patients and their families. We will advance the development of an implantable long-term antipsychotic delivery system to improve medication adherence in schizophrenia. We will also determine how constant infusion of antipsychotic medication from implants improves behavior and brain function in comparison to oral administration rodents.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS)
Program Officer
Freund, Michelle
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Tatard-Leitman, Valerie M; Jutzeler, Catherine R; Suh, Jimmy et al. (2015) Pyramidal cell selective ablation of N-methyl-D-aspartate receptor 1 causes increase in cellular and network excitability. Biol Psychiatry 77:556-68
Featherstone, R E; Nagy, L R; Hahn, C G et al. (2014) Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice. Drug Alcohol Depend 134:123-7
Billingslea, Eddie N; Tatard-Leitman, Valerie M; Anguiano, Jaynie et al. (2014) Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits. Neuropsychopharmacology 39:1603-13
Siegel, Steven J; Talpos, John C; Geyer, Mark A (2013) Animal models and measures of perceptual processing in schizophrenia. Neurosci Biobehav Rev 37:2092-8
Siegel, Steven J (2013) Capacity, confidentiality and consequences: balancing responsible medical care with mental health law. Curr Psychiatry Rep 15:380
Wang, Cheng-Kuo; Wang, Wan-Yi; Meyer, Robert F et al. (2010) A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process. J Biomed Mater Res B Appl Biomater 93:562-72
Amann, Laura C; Gandal, Michael J; Lin, Robert et al. (2010) In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res 27:1730-7
Rabin, C; Liang, Y; Ehrlichman, R S et al. (2008) In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res 98:66-78